Catalyst Event
HLB Co Ltd (028300) · Other
From Akros SCHK HK-Korea Cosmetics Index (ASHKCOS)
9/27/2026, 12:00:00 AM
FDA decision on New Drug Application for Lirafugratinib as a second-line treatment for bile duct cancer, which was granted priority review and carries an estimated >10% price impact, scheduled.
Korean Translation
우선심사 대상으로 지정된 담관암 2차 치료제 리라푸그라티닙의 신약허가신청(NDA)에 대한 FDA 승인 여부 결정(10% 이상의 주가 영향 예상) 예정됨.
Related Recent Events
HLB Co Ltd (028300) · Other
FDA decision on New Drug Application for Rivoceranib and Camrelizumab combination therapy as a first-line treatment for liver cancer, following a 'Class 2' resubmission in January 2026 and carrying an estimated >10% price impact, scheduled.
7/23/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
6/24/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
SK Biopharmaceuticals Co Ltd (326030) · Other
SK Biopharmaceuticals is scheduled to be removed from the MSCI Korea Index effective at the close of May 29, 2026, following an announcement on May 12, 2026, which may lead to passive fund outflows, scheduled. Medium impact estimated due to expected passive fund outflows.
5/29/2026, 12:00:00 AM
CSPC Pharmaceutical Group Ltd (1093) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast revenue of 7.52B HKD. Estimated Medium importance as earnings results typically drive significant price movement scheduled.
5/27/2026, 12:00:00 AM
ANTA Sports Products Limited (2020) · Other
Adjustment to the conversion price of EUR 1.5 billion convertible bonds from HK$101.13 to HK$99.80 effective May 19, 2026; technical adjustment with minimal price impact expected, scheduled.
5/19/2026, 12:00:00 AM